14:01 03/12/2016 Stock to Watch: Pfizer Inc. (NYSE:PFE)
Stock to Watch: Pfizer Inc. (NYSE:PFE)
Post Registrar - 20 hours ago
Pfizer Inc. (NYSE:PFE) share price plunged 0.54% or +0.17 points to reach at $31.63 during previous trading session. The stock's price fluctuated within the range of $31.36– $31.73 during previous trading session.
Exxonmobil Investment Management Inc. TX Cuts Stake in Pfizer Inc. (PFE) - The Cerbat Gem
Trade: Today, Pfizer Inc. (PFE) Issues FY16 Earnings Guidance - DailyQuint

12:56 01/12/2016 LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Business Wire (press release) - Dec 1, 2016
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to 16 ...
Pfizer's Lyrica successful in late-stage study in pediatric epilepsy - Seeking Alpha
Pfizer Reports Positive Lyrica Study (PFE) - Investopedia

22:41 30/11/2016 Pfizer Inc. (PFE) Stake Decreased by Windsor Financial Group LLC
Pfizer Inc. (PFE) Stake Decreased by Windsor Financial Group LLC
The Cerbat Gem - Nov 30, 2016
Pfizer logo Windsor Financial Group LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 3.5% during the third quarter, according to its most recent disclosure with the SEC.
Analysts Advise About Pfizer Inc. (NYSE:PFE) - The Independent Republic
Active Stock Momentum: Pfizer Inc. (NYSE:PFE) - FactsReporter

13:30 30/11/2016 Pfizer Announces Positive Top-Line Results from the Pivotal Comparative ...
Pfizer Announces Positive Top-Line Results from the Pivotal Comparative ...
Business Wire (press release) - Nov 30, 2016
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint.
Pfizer Inc. (NYSE:PFE) & General Growth Properties Inc (NYSE:GGP) Worth ... - Money News
Pfizer Inc. (NYSE:PFE)'s Herceptin biosim posts 'encouraging' phase 3 data - Benchmark Monitor

15:45 29/11/2016 analysts Estimates and Ratings: Pfizer Inc. (NYSE:PFE)
analysts Estimates and Ratings: Pfizer Inc. (NYSE:PFE)
News Oracle - Nov 29, 2016
Pfizer Inc. (NYSE:PFE) will report its next earnings on Jan 31 - Feb 6 (Est.). The company reported the earnings of $0.61/Share in the last quarter where the estimated EPS by analysts was $0.62/share.

15:45 29/11/2016 Pfizer Inc. (NYSE:PFE), Eli Lilly And Co (NYSE:LLY) Impotence Drugs Price ...
Pfizer Inc. (NYSE:PFE), Eli Lilly And Co (NYSE:LLY) Impotence Drugs Price ...
Market Exclusive - Nov 29, 2016
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co (NYSE:LLY) are yet again the subject of immense criticism as their practice of increasing the prices of key drugs in the impotence drug market in tandem continues to leave patients with no other options.

15:33 28/11/2016 what are Analysts report about: Pfizer Inc. (NYSE:PFE)
what are Analysts report about: Pfizer Inc. (NYSE:PFE)
News Oracle - Nov 28, 2016
Pfizer Inc. (NYSE:PFE) will report its next earnings on Jan 31 - Feb 6 (Est.). The company reported the earnings of $0.61/Share in the last quarter where the estimated EPS by analysts was $0.62/share.
Stock's Buzzers: Canadian Natural Resources Limited (NYSE:CNQ), Pfizer Inc ... - TRA

22:18 22/11/2016 One of the world's premier biopharmaceutical companies, Pfizer Inc. will lease ...
One of the world's premier biopharmaceutical companies, Pfizer Inc. will lease ...
Area Development Online - Nov 22, 2016
To support Pfizer's new facility, the state has offered a strategic economic incentive package that the company can receive if it meets strict job creation criteria.
Pfizer to move to new $200 million Chesterfield campus, keep 450 jobs - STLtoday.com
Pfizer announces plans to move into new $200M facility in St. Lo - KMOV.com - KMOV.com

21:23 09/11/2016 Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.
Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.
Motley Fool - Nov 9, 2016
Pfizer can claim two things that Gilead can't: Revenue is rising and so are earnings (at least on a non-GAAP basis). The pharmaceutical company still has its own risks, though. Legacy established products continue to drag down overall growth. Sales are ...
Gilead Sciences, Inc. (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE): Why Drug Stocks ... - Smаrt Stоck Nеws

16:18 07/11/2016 Is Pfizer Inc.'s 6.4% Drop in October the Beginning of a Long Downtrend?
Is Pfizer Inc.'s 6.4% Drop in October the Beginning of a Long Downtrend?
Motley Fool - Nov 7, 2016
Shares of global drug giant Pfizer (NYSE:PFE) had a pretty miserable October, ending lower by 6.4% based on data from S&P Global Market Intelligence, and things haven't improved through the first few days of November following its third-quarter ...
Pfizer Inc.: Why is PFE Stock Going Nuts Today? - Income Investors
Pfizer Inc. (NYSE:PFE): Why Is PFE Stock Going Nuts Today? - Profit Confidential